Payment overview · 2025
General Payments
$299.11
19 reported records · 9 companies
Healthcare provider profile · identity verified
Jonathan Patmor Maddux, MD
Allopathic & Osteopathic Physicians|Family Medicine · MARION, KY · NPI 1417194689
Verified facts
What the public records show
CMS Open Payments records show Jonathan Patmor Maddux, MD received $299.11 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 48.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Farxiga, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Aristada by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $144.95 | 48.5% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.82 | 11.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.84 | 7.3% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $19.29 | 6.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.57 | 6.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.19 | 5.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.09 | 5.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.28 | 5.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.08 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $299.11 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $89.23 | 6 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
240 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 726 | 161 |
| Atorvastatin Calcium | Atorvastatin Calcium | 718 | 141 |
| Gabapentin | Gabapentin | 636 | 115 |
| Omeprazole | Omeprazole | 555 | 118 |
| Metformin Hcl | Metformin Hcl | 480 | 102 |
| Furosemide | Furosemide | 472 | 97 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 442 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 388 | 60 |
| Alprazolam | Alprazolam | 345 | 52 |
| Potassium Chloride | Potassium Chloride | 336 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 332 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 304 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 281 | 61 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 280 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 275 | 46 |
| Trazodone Hcl | Trazodone Hcl | 275 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 61 |
| Losartan Potassium | Losartan Potassium | 260 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 60 |
| Eliquis | Apixaban | 240 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 46 |
| Famotidine | Famotidine | 214 | 43 |
| Buspirone Hcl | Buspirone Hcl | 213 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 27 |
| Sertraline Hcl | Sertraline Hcl | 200 | 38 |
| Simvastatin | Simvastatin | 200 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 189 | 57 |
| Tramadol Hcl | Tramadol Hcl | 188 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 52 |
| Baclofen | Baclofen | 171 | 16 |
| Xarelto | Rivaroxaban | 164 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 147 | 39 |
| Clonazepam | Clonazepam | 146 | 26 |
| Warfarin Sodium | Warfarin Sodium | 143 | 13 |
| Lorazepam | Lorazepam | 141 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 139 | 23 |
| Allopurinol | Allopurinol | 136 | 35 |
| Azithromycin | Azithromycin | 134 | 113 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 131 | 27 |
| Levofloxacin | Levofloxacin | 130 | 85 |
| Montelukast Sodium | Montelukast Sodium | 118 | 16 |
| Celecoxib | Celecoxib | 115 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 17 |
| Januvia | Sitagliptin Phosphate | 111 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 19 |
| Nystatin | Nystatin | 107 | 59 |
| Carvedilol | Carvedilol | 106 | 20 |
| Divalproex Sodium | Divalproex Sodium | 105 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 105 | 30 |
| Spironolactone | Spironolactone | 105 | 24 |
| Meclizine Hcl | Meclizine Hcl | 102 | 33 |
| Ibuprofen | Ibuprofen | 101 | 20 |
| Clonidine Hcl | Clonidine Hcl | 100 | 27 |
| Meloxicam | Meloxicam | 98 | 29 |
| Atenolol | Atenolol | 96 | 23 |
| Prednisone | Prednisone | 96 | 59 |
| Amitriptyline Hcl | Amitriptyline Hcl | 93 | 14 |
| Amoxicillin | Amoxicillin | 91 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 89 | 17 |
| Diazepam | Diazepam | 87 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 86 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 34 |
| Bumetanide | Bumetanide | 85 | 19 |
| Sucralfate | Sucralfate | 85 | 20 |
| Cefdinir | Cefdinir | 84 | 59 |
| Methylprednisolone | Methylprednisolone | 83 | 69 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 80 | 13 |
| Chlorthalidone | Chlorthalidone | 79 | 15 |
| Donepezil Hcl | Donepezil Hcl | 79 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 78 | 62 |
| Bupropion Xl | Bupropion Hcl | 76 | 14 |
| Pregabalin | Pregabalin | 76 | 14 |
| Finasteride | Finasteride | 75 | 15 |
| Memantine Hcl | Memantine Hcl | 75 | 12 |
| Mirtazapine | Mirtazapine | 73 | 13 |
| Oxcarbazepine | Oxcarbazepine | 73 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | 13 |
| Ozempic | Semaglutide | 70 | 14 |
| Fluconazole | Fluconazole | 69 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 14 |
| Mupirocin | Mupirocin | 68 | 46 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 16 |
| Ondansetron Odt | Ondansetron | 65 | 31 |
| Topiramate | Topiramate | 64 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 11 |
| Metformin Hcl Er | Metformin Hcl | 57 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 56 | suppressed |
| Glipizide | Glipizide | 55 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 15 |
| Promethazine Hcl | Promethazine Hcl | 54 | 16 |
| Colestipol Hcl | Colestipol Hcl | 53 | 11 |
| Temazepam | Temazepam | 51 | suppressed |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 50 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 35 |
| Ramipril | Ramipril | 48 | 11 |
| Klor-Con M20 | Potassium Chloride | 47 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 22 |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Risperidone | Risperidone | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 43 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 43 | suppressed |
| Tradjenta | Linagliptin | 43 | suppressed |
| Carbamazepine | Carbamazepine | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Lidocaine | Lidocaine | 34 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 33 | 24 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | suppressed |
| Admelog Solostar | Insulin Lispro | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 17 |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Multaq | Dronedarone Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 17 |
| Latanoprost | Latanoprost | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Xtampza Er | Oxycodone Myristate | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Secuado | Asenapine | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Dantrolene Sodium | Dantrolene Sodium | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Moexipril Hcl | Moexipril Hcl | 15 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Flurbiprofen | Flurbiprofen | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Aristada | Aripiprazole Lauroxil | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $299.11 · 19 records | Novo Nordisk Inc | ARISTADA, CAPLYTA, ETERNA, FARXIGA, LYBALVI, MOUNJARO, NURTEC ODT, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error